Abbott Laboratories (ABT) Shares Bought by Huber Financial Advisors LLC

Huber Financial Advisors LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 19.3% during the 1st quarter, HoldingsChannel reports. The fund owned 13,754 shares of the healthcare product maker’s stock after purchasing an additional 2,225 shares during the period. Abbott Laboratories accounts for approximately 0.5% of Huber Financial Advisors LLC’s portfolio, making the stock its 27th biggest holding. Huber Financial Advisors LLC’s holdings in Abbott Laboratories were worth $1,100,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. 1 North Wealth Services LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $33,000. Beacon Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $38,000. Brand Asset Management Group Inc. grew its stake in shares of Abbott Laboratories by 66.7% in the 4th quarter. Brand Asset Management Group Inc. now owns 500 shares of the healthcare product maker’s stock valued at $36,000 after buying an additional 200 shares in the last quarter. WP Advisors LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $46,000. Finally, Exane Derivatives bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $42,000. 73.58% of the stock is currently owned by institutional investors.

In other news, CFO Brian B. Yoor sold 2,246 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $78.00, for a total transaction of $175,188.00. Following the completion of the transaction, the chief financial officer now directly owns 116,627 shares in the company, valued at $9,096,906. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jared Watkin sold 309,429 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $78.51, for a total value of $24,293,270.79. Following the transaction, the insider now owns 189,227 shares of the company’s stock, valued at $14,856,211.77. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 551,643 shares of company stock valued at $42,471,501. Corporate insiders own 0.70% of the company’s stock.

ABT has been the subject of several recent research reports. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Royal Bank of Canada boosted their price target on Abbott Laboratories to $82.00 and gave the company a “buy” rating in a research note on Monday, April 15th. They noted that the move was a valuation call. Bank of America reissued a “buy” rating and issued a $81.00 price target (up previously from $73.00) on shares of Abbott Laboratories in a research note on Thursday, February 7th. Wells Fargo & Co restated a “buy” rating on shares of Abbott Laboratories in a report on Thursday, March 14th. Finally, BTIG Research restated a “hold” rating on shares of Abbott Laboratories in a report on Thursday, January 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.30.

ABT opened at $75.63 on Friday. Abbott Laboratories has a twelve month low of $60.31 and a twelve month high of $80.74. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.58 and a quick ratio of 1.13. The company has a market capitalization of $134.54 billion, a P/E ratio of 26.26, a P/E/G ratio of 2.14 and a beta of 1.11.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.02. Abbott Laboratories had a return on equity of 16.86% and a net margin of 8.53%. The firm had revenue of $7.54 billion during the quarter, compared to analyst estimates of $7.49 billion. During the same period in the previous year, the company earned $0.59 EPS. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. Equities analysts expect that Abbott Laboratories will post 3.22 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Abbott Laboratories (ABT) Shares Bought by Huber Financial Advisors LLC” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.wkrb13.com/2019/05/24/abbott-laboratories-abt-shares-bought-by-huber-financial-advisors-llc.html.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.